Recombinant erythropoietin improves cognitive function in chronic haemodialysis patients

Temple, R. M.; Langan, S. J.; Deary, I. J.; Winney, R. J.

doi:10.1093/oxfordjournals.ndt.a092113

Cited by 33 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were reported from studies on cognitive functions in chronic dialysis patients receiving epoetin-a. Two studies described significant relationship between hemoglobin levels and ERP P300 latency scores [14][15][16][17][18]. However, in that study cognitive dysfunction, which seems correlated with low hemoglobin values does not recover completely even in the patients with normal hemoglobin levels.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Cognitive dysfunction in β‐thalassemia minor

et al. 2006

View full text Add to dashboard Cite

Turkey b-thalassemia minor is a common, hereditary, and mostly symptomless disease. Previous studies have shown that lower hemoglobin values are associated with poorer cognitive functions. We aimed to evaluate the cognitive function in patients with b-thalassemia minor. Thirty-two male subjects with b-thalassemia minor and 32 sex-, age-, and education statusmatched healthy subjects were enrolled in the study. Blood tests and P300 potentials were carried out. P300 potential latency in all patients was significantly longer than those in the control group (337.63 ± 34.89 msec and 310.66 ± 14.30 msec, respectively; t 4.046, P < 0.001). The amplitudes of P300 in patient group were significantly lower than those in the control group (5.19 ± 3.59 lV and 9.81 ± 3.33 lV, respectively; t 5.349, P < 0.001). In this study, we have found that P300 potentials are adversely affected for cognitive functions in patients with b-thalassemia minor. Am. J. Hematol. 82:203-207, 2007. V V C 2006 Wiley-Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 91%

“…Studies on the effects of epoetin-a administration on cognitive functions in patients with end-stage kidney failure have shown improvement of neuropsyhiatric indices of cognitive functions and electroencephalographical measures of ERP after the institution of epoetin-a [12][13][14][15][16][17][18][19].…”

Section: Discussionmentioning

confidence: 99%

Cognitive dysfunction in β‐thalassemia minor

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Cognitive dysfunction has been reported in HD patients [4, 38, 39, 40, 41, 42, 43, 44, 45]. Several studies have also demonstrated that correction of anemia with recombinant human erythropoietin is often associated with significant improvement of the cognitive function [41, 42, 43], especially in the frontal cortex [41, 42]. Marsh et al [41]reported a significant increase in brain evoked potentials, which were highest in the frontal zone, after achieving a target hematocrit of around 30%.…”

Section: Discussionmentioning

confidence: 99%

Dialysis-Related Hypotension as a Cause of Progressive Frontal Lobe Atrophy in Chronic Hemodialysis Patients: A 3-Year Prospective Study

et al. 2004

View full text Add to dashboard Cite

Background/Aim: Brain atrophy is known to develop more rapidly in hemodialysis (HD) patients than other individuals. The present study was designed to examine the role of HD-related hypotension in brain atrophy in patients on chronic HD. Methods: By using magnetic resonance imaging, whole brain atrophy was assessed by the ventricular-brain ratio (VBR; ventricular area/whole brain area). Frontal brain atrophy was assessed by the frontal atrophy index (FAI; frontal brain area/intracranial frontal space). The number of lacunae was also counted. We studied 32 HD patients without symptomatic neurological abnormalities or diabetes mellitus: male/female ratio 19/13; mean age ± SD 53 ± 10 (range 28–77) years; mean HD duration ± SD 11 ± 6 (range 1–22) years. Magnetic resonance imagings were taken in 1995 and 1998. All dialysis-related hypotension episodes during the same period were identified from the medical records and counted. Results: The VBR ranged from 8.8 to 18.7% in 1995 (12.8 ± 2.2%) and was not different in 1998 (13.1 ± 2.7%). However, the VBR increased by more than 5% in 14 patients, and their HD duration of 13 ± 6 years was significantly longer than that of 18 patients with stable VBR (p < 0.05). The FAI in 1995 was 62.2 ± 4.2% (range 55.8–71.3%) and decreased significantly to 59.7 ± 4.7% (range 50.2–70.9%) in 1998 (p < 0.05). The change in FAI correlated significantly with both the total number of dialysis-related hypotension episodes (r = 0.45, p < 0.05) and the increase in number of lacunae (r = 0.42, p < 0.05). Conclusion: Our results suggest that dialysis-related hypotension plays a role in progressive frontal lobe atrophy in HD patients.

show abstract

“…Hypoxia also obstructs cognitive function and brain metabolism, which consumes about 20% of whole body oxygen supply. [1][2][3][4][5][6] Some studies of the optimal hematocrit (Hct opt ) have been reported. 3,[7][8][9] The Hct opt proposed by the Working Group of the Japanese Ministry of Welfare 10 is 30%, while the guidelines of the National Kidney Foundation (NKF) 11 propose 33% to 36%.…”

Section: Introductionmentioning

confidence: 99%

Optimal hematocrit based on regional cerebral blood flow in hemodialysis patients with diabetic nephropathy

Sakayori

Kamano

et al. 2002

Clinical and Experimental Nephrology

View full text Add to dashboard Cite

Background. The optimal hematocrit (Hct opt ) in hemodialysis (HD) patients has yet to be determined based on the etiology and complications of their endstage renal disease (ESRD). To investigate this problem, we compared regional cerebral oxygen supply (rCOS) in diabetic (DM group) and non-diabetic HD patients (non-DM group) with data from subjects without renal disease or DM (control group). Methods. Regional cerebral blood flow (rCBF) was measured with single-photon emission computed tomography (SPECT) by the N-isopropyl-p-[ 123 I]-iodoamphetamine ( 123 I-IMP)-autoradiographic (ARG) method, and both the O 2 content (O 2 CT) of arterial blood and hematocrit (Hct) were evaluated. Using the regression lines of rCBF vs Hct and O 2 CT vs Hct, we established a convex curve between rCOS and Hct. The peak of the curve indicates the maximum rCOS (rCOS max ) and Hct opt for rCOS max . Results. The rCBF in both the DM and non-DM groups was lower than that of the control group at the same Hct level, and the DM group had the lowest values. The rCOS max values in the DM and non-DM groups were nearly equal, but both were lower than in controls. The Hct opt in the DM group was lower than that in the non-DM group by 6.3% Ϯ 3.3%. Conclusions. Although the difference in Hct opt values in the DM and non-DM groups was 6.3%, the rCOS max values in both groups were nearly equal. This suggests that differences in the Hct opt may depend on complications or causes of ESRD. The optimal Hct in the DM group was 22.6% Ϯ 1.9%, and that for the non-DM group was 29.0% Ϯ 1.8%.

show abstract

Recombinant erythropoietin improves cognitive function in chronic haemodialysis patients

Cited by 33 publications

References 0 publications

Cognitive dysfunction in β‐thalassemia minor

Cognitive dysfunction in β‐thalassemia minor

Dialysis-Related Hypotension as a Cause of Progressive Frontal Lobe Atrophy in Chronic Hemodialysis Patients: A 3-Year Prospective Study

Optimal hematocrit based on regional cerebral blood flow in hemodialysis patients with diabetic nephropathy

Contact Info

Product

Resources

About